Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

ABSTRACT:

Purpose

A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC). Final survival analyses and updated results are reported.

Patients and methods

Seven hundred fifty treatment-naïve patients with metastatic clear cell RCC were randomly assigned to sunitinib 50 mg orally once daily on a 4 weeks on, 2 weeks off dosing schedule or to IFN-alpha 9 MU subcutaneously thrice weekly. Overall survival was compared by two-sided log-rank and Wilcoxon tests. Progression-free survival, response, and safety end points were assessed with updated follow-up.

Results

Median overall survival was greater in the sunitinib group than i

SUBMITTER: Motzer RJ 

PROVIDER: S-EPMC3646307 | biostudies-literature | 2009 Aug

REPOSITORIES: biostudies-literature